Compare GBCI & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBCI | COGT |
|---|---|---|
| Founded | 1955 | 2014 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.5B |
| IPO Year | 1996 | 2018 |
| Metric | GBCI | COGT |
|---|---|---|
| Price | $49.74 | $38.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $53.60 | $33.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-22-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | N/A | ★ $7,871,000.00 |
| Revenue This Year | $26.01 | N/A |
| Revenue Next Year | $8.75 | $506.58 |
| P/E Ratio | $33.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.76 | $3.72 |
| 52 Week High | $53.99 | $43.73 |
| Indicator | GBCI | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 54.64 |
| Support Level | $50.37 | $36.03 |
| Resistance Level | $52.18 | $39.82 |
| Average True Range (ATR) | 1.58 | 1.88 |
| MACD | -0.40 | 0.06 |
| Stochastic Oscillator | 13.74 | 65.39 |
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.